Patient confidence key in switching delivery of biosimilars 05-Feb-2020 By Ben Hargreaves As developers of biosimilars look at ways of differentiating from originator products, experts warn that patients will need to be brought on board.
Celltrion gets EMA nod for subcutaneous infliximab biosimilar 28-Nov-2019 By Vassia Barba Celltrion receives EMA marketing authorisation for Remsima SC, the first subcutaneously-administered option for delivery of infliximab, a treatment for rheumatoid arthritis.
UPDATED Celltrion gets FDA approval for antibiotic generic 01-May-2019 By Maggie Lynch The South Korean company receives approval from the FDA for generic antibiotic, linezolid.